AJP - Regu Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 292: R328-R336, 2007. First published August 31, 2006; doi:10.1152/ajpregu.00561.2006
0363-6119/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/1/R328    most recent
00561.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lang, C. H.
Right arrow Articles by Frost, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lang, C. H.
Right arrow Articles by Frost, R. A.

INFLAMMATION AND CYTOKINES

Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I

Charles H. Lang, Danuta Huber, and Robert A. Frost

Department of Cellular and Molecular Physiology and Department of Surgery, Pennsylvania State University College of Medicine, Hershey, Pennsylvania

Submitted 8 August 2006 ; accepted in final form 30 August 2006


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The present study determined whether thermal injury increases the expression of the ubiquitin (Ub) E3 ligases referred to as muscle ring finger (MuRF)-1 and muscle atrophy F-box (MAFbx; aka atrogin-1), which are muscle specific and responsible for the increased protein breakdown observed in other catabolic conditions. After 48 h of burn injury (40% total body surface area full-thickness scald burn) gastrocnemius weight was reduced, and this change was associated with an increased mRNA abundance for atrogin-1 and MuRF-1 (3.1- to 8-fold, respectively). Similarly, burn increased polyUb mRNA content in the gastrocnemius twofold. In contrast, there was no burn-induced atrophy of the soleus and no significant change in atrogin-1, MuRF-1, or polyUb mRNA. Burns also did not alter E3 ligase expression in heart. Four hours after administration of the anabolic agent insulin-like growth factor (IGF)-I to burned rats, the mRNA content of atrogin-1 and polyUb in gastrocnemius had returned to control values and the elevation in MuRF-1 was reduced 50%. In contrast, leucine did not alter E3 ligase expression. In a separate study, in vivo administration of the proteasome inhibitor Velcade prevented burn-induced loss of muscle mass determined at 48 h. Finally, administration of the glucocorticoid receptor antagonist RU-486 did not prevent burn-induced atrophy of the gastrocnemius or the associated elevation in atrogin-1, MuRF-1, or polyUb. In summary, the acute muscle wasting accompanying thermal injury is associated with a glucocorticoid-independent increase in the expression of several Ub E3 ligases that can be downregulated by IGF-I.

muscle atrophy F-box; muscle wasting; leucine

EXTENSIVE THERMAL INJURY [e.g., >40% total body surface area (TBSA)] is a potent catabolic insult leading to a sustained hypermetabolic condition characterized by the erosion of lean body mass (61). When protracted, the depletion of both myofibrillar and sarcoplasmic protein leads to muscle weakness (14). Importantly, although this protein imbalance is observed acutely after injury it may persist for up to a year after the original burn insult (25), thereby impairing recovery. This wasting is associated with a greater risk for septic complications, longer hospital stays, and delayed rehabilitation (31, 59, 60). In general, the morbidity in this patient population is proportional to the magnitude of the catabolic response (25) and is considered a determinant of long-term patient outcomes (23). Tissue protein content in general and skeletal muscle protein in particular are maintained by the dynamic balance between rates of protein synthesis and degradation (36). Several catabolic insults, including sepsis, endotoxin, and excess inflammatory cytokines and glucocorticoids, alter both protein synthesis and degradation (16, 26, 34, 38, 39). In contrast, several laboratories have reported that burn-induced atrophy appears to result primarily from an elevated rate of muscle proteolysis (4, 11, 16, 30, 32, 39, 53, 59, 63). The etiology of this accelerated rate of protein degradation leading to negative nitrogen balance in burn injury is not completely understood.

Skeletal muscle contains multiple distinct pathways [e.g., lysosomal, calcium dependent, and ubiquitin (Ub)-proteasome dependent] responsible for regulating proteolysis (45), and, under certain experimental conditions, all of these pathways have been reported to be upregulated by thermal injury (11, 16, 17, 20). However, burn- and stress-induced changes in the Ub-proteasome proteolytic pathway are generally regarded as relatively more important in mediating the muscle cachexia observed after burn (27). In this regard, thermal injury to rats concomitantly increased muscle proteasome activity determined in vitro as well as the mRNA content of the 20 S proteasome {alpha}-subunits RC2 and RC3, the beta-subunit RC7 (8, 17), and Ub (18, 19). Furthermore, the gene expression of the 14-kDa Ub-conjugating enzyme E214K is also increased in muscle from burned rats (8, 21). Finally, in vitro treatment of incubated muscles from burned rats with proteasome inhibitors reverses the increased rate of protein degradation (17); however, comparable studies have not yet been reported in which the proteasome inhibitor has been administered in vivo in an attempt to ameliorate the burn-induced muscle wasting.

Until recently the Ub-conjugating enzyme E2 and the Ub ligase E3{alpha} were considered the primary enzymes regulating muscle proteolysis in wasting states (28). However, a host of diverse conditions manifesting muscle atrophy, such as immobilization, denervation, and dexamethasone or inflammatory cytokine treatment, have all been reported to increase the gene expression of two additional E3 ligases—muscle ring finger (MuRF)-1 and muscle atrophy F-box (MAFbx; aka atrogin-1)—that are muscle specific (6). Furthermore, transgenic mice with null alleles for each gene individually display a robust resistance to denervation-induced atrophy (6), establishing an unequivocal in vivo role for MuRF-1 and atrogin-1 in promoting skeletal muscle degradation. Subsequent studies showed that diabetes, renal failure, as well as more traditional inflammatory conditions including cancer cachexia, peritonitis, and endotoxemia also increased expression of these "atrogenes" (13, 22, 44, 62). However, the response of atrogin-1 and MuRF-1 to burn injury has not been reported. Therefore, the purpose of the present study was to determine whether skeletal muscle atrogin-1 and MuRF-1 mRNA content is increased after burn and whether the resultant wasting observed can be ameliorated in vivo by treatment with the proteasome inhibitor Velcade (1, 43). Moreover, we examined the ability of the anabolic agents insulin-like growth factor (IGF)-I and leucine to acutely regulate mRNA expression of these genes as well as examining whether any burn-induced changes were glucocorticoid dependent.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animal preparation and experimental protocol. Adult specific pathogen-free male Sprague-Dawley rats (275–300 g for study 1 and 300–325 g for all other studies; Charles River Breeding Laboratories, Cambridge, MA) were housed at a constant temperature, exposed to a 12:12-h light-dark cycle, and maintained on standard rodent chow and water ad libitum for at least 1 wk before experiments were performed. All experiments were approved by the Animal Care and Use Committee at the Pennsylvania State University College of Medicine and adhered to the National Institutes of Health (NIH) guidelines for the use of experimental animals.

Rats in all studies were deeply anesthetized with an intraperitoneal injection of pentobarbital sodium (60–75 mg/kg body wt). The hair on the dorsal and ventral surfaces of the animal was closely clipped, and animals were secured in an insulated template that exposed only the area of skin to be injured, as originally reported by Walker and Mason (58) and described and characterized by our laboratory (39–42). For the burn group, the surface of the skin exposed through the aperture in the template was immersed in 100°C water for 12 s on the dorsal surface and 7 s on the ventral surface. The template limits the burn area to a predetermined 40% TBSA, and the technique produces a full-thickness scald injury with complete destruction of the underlying neural tissue. Rats were immediately dried and resuscitated by the subcutaneous injection of 0.9% saline (10 ml). Sham burn control rats were treated identically to those in the burn group, except they were immersed in 25°C water. All rats were injected subcutaneously with the analgesic buprenorphine (0.2 mg/kg) immediately after sham or burn injury and again 24 h later. Rats were returned to individual cages for the remainder of the experimental protocol. Burn rats displayed no discomfort or pain and moved freely within their cage. As described below, the majority of the experiments were performed ~48 h after the burn because previous studies indicated that severe alterations in skeletal muscle protein balance are observed at this time point (42) and because of the results from the first experimental series. In this study and unless otherwise indicated, burn rats were permitted to consume food (Harlan no. 2018, 18% protein rodent diet; Madison, WI) ad libitum and control rats were pair fed to match the food consumption of animals in the burn group. Previous studies indicated that during the first 24-h period after burn injury rats consumed 72 ± 5% of normal food consumption and thereafter food consumption was not significantly different from basal control values (data not shown). Therefore, any burn-induced changes in the expression of atrogin-1 and MuRF-1 cannot be attributed to differences in the caloric intake between control and burn rats.

In the first study, a limited time-course study was performed to determine the temporal progression of burn-induced changes in atrogin-1 and MuRF-1 mRNA in gastrocnemius. Therefore, rats were anesthetized and muscle was sampled at various time points from 12 h to 5 days after burn injury.

In the second study, animals in both the control (e.g., nonburned) and burn groups were then administered either saline (0.155 mol/l) or 200 µg/kg body wt IGF-I subcutaneously. Comparable doses have been shown to increase muscle protein synthesis (5). Rats were returned to individual cages and anesthetized 4 h later by an intraperitoneal injection of pentobarbital sodium (75 mg/kg body wt). Thereafter, a blood sample (1 ml) was collected from the abdominal aorta, and the gastrocnemius, soleus, and heart (e.g., ventricle only) were excised. This time point was selected based on studies indicating that IGF-I maximally decreased atrogin-1 mRNA content in C2C12 myotubes within this time frame (56).

In a third group of burn and control rats we investigated the ability of the branched-chain amino acid leucine to alter E3 ligase expression. Leucine is a potent nutrient signal reported to both increase protein synthesis and decrease protein degradation (3, 7, 24, 51). For this study, rats were administered either saline (0.155 mol/l) or 1.35 g/kg body wt leucine (prepared as 54.0 g/l of L-amino acid in distilled water) by oral gavage. This dose of leucine was selected because it is equivalent to the amount of leucine consumed in a 24-h period when rats of this age and strain are provided free access to food and it simulates muscle protein synthesis (3). As for the studies using IGF-I described above, tissues were sampled 4 h after leucine administration.

In the fourth experimental series, burn rats were treated 2 h before burn injury with the proteasome inhibitor Velcade (0.3 mg/kg body wt administered ip; Millennium Pharmaceuticals, Cambridge, MA) or an equal volume (1.5 ml) of vehicle (saline). Comparable doses were previously shown to reduce chronic inflammation induced by the injection of streptococcal cell wall (54) and atrophy induced by hindlimb immobilization (33) as well as to inhibit proteasome function (43). This time point was selected to accentuate the burn-induced decrease in muscle protein content and to optimize detection of a Velcade effect. All rats were pair fed to match food consumption by the burn + Velcade group.

In the final study, control and burn rats were injected subcutaneously with the type II glucocorticoid receptor antagonist RU-486 (Mifepristone, 20 mg/kg body wt; Sigma, St. Louis, MO) 2 h before burn or sham injury and again 24 h later; time-matched control animals were injected with an equal volume (0.3 ml) of vehicle [ethanol-saline 1:1 (vol/vol)]. RU-486 is an antiprogestin with antiglucocorticoid properties (51). The dose of RU-486 used in the present study attenuates glucocorticoid-induced increases in catabolism and ameliorates endotoxin- or cytokine-induced changes in the IGF system (15, 65).

PolyUb immunoblot. Gastrocnemius was homogenized in 4 volumes of ice-cold buffer containing (in mM) 20 HEPES, pH 7.4, 2 EGTA, 50 NaF, 100 KCl, 0.2 EDTA, 50 beta-glycerophosphate, 10 N-ethylmaleimide, 0.1 PMSF, 1 benzamidine, and 0.5 sodium vanadate. Homogenates were centrifuged and Western blot analysis performed exactly as previously described (33).

Northern blot analysis of Ub ligases. Total RNA was isolated from rat tissues with TRI Reagent (Molecular Research Center, Cincinnati, OH) according to the manufacturer's protocol. Samples (25 µg) of total RNA were run under denaturing conditions in 1.1% agarose-6% formaldehyde gels using 1x HEPES running buffer. Northern blotting occurred via capillary transfer to Nytran SuPerCharge membranes (Schleicher & Schuell, Keene, NH). Rat oligonucleotides MAFbx/atrogin-1 (5'-CCCACCAGCACGGACTTGCCGACTCTCTGGACC-AGCGTGC-3'), MuRF-1(5'-AGCGGAAACGACCTCCAGACATGGACACCGAGCCACCGCG-3'), and polyUb (5'-GGATCTTGGCCTTCACGTTCTCGATGGTGTCACTGGGCTC-3') were synthesized (IDT, Coralville, IA) and radioactively labeled with terminal deoxynucleotidyl transferase (Promega, Madison, WI). For normalization of RNA loading, an 18S oligonucleotide was labeled by the same method. Northern blots were hybridized with ULTRAhyb (Ambion, Austin, TX). All membranes were initially washed twice in 2x saline sodium citrate (SSC)-0.1% SDS for 5 min at 42°C and once in 0.2x SSC-0.1% SDS for 15 min at 42°C. All probes except 18S were additionally washed with 0.2x SSC-0.1% SDS for 10 min at 48°C. Finally, membranes were exposed to a PhosphorImager screen (Molecular Dynamics, Sunnyvale, CA), visualized, and quantified with Molecular Dynamics ImageQuant software (version 5.2).

A portion of powdered muscle was homogenized in saline, and the protein concentration was determined by the Biuret method, using crystalline bovine serum albumin as a standard. Muscle protein content was calculated as the product of the muscle weight (g) and the muscle protein concentration (mg protein/wet wt of muscle). We previously reported (42) that the wet weight-to-dry weight ratio for gastrocnemius is not altered by burn.

Statistical analysis. Experimental data for each condition are summarized as means ± SE, and the sample size is indicated in Figs. 1–4, 6, and 7 and Table 1. Statistical evaluation of the data from studies with four groups was performed with ANOVA followed by Student-Neuman-Keuls test to determine treatment effect (Instat; San Diego, CA). Differences between the groups were considered significant when P < 0.05.


Figure 1
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 1. Time-dependent changes in atrogin-1 (top) and muscle ring factor (MuRF)-1 (bottom) mRNA content in muscle after burn injury. Rats were anesthetized and a 40% scald injury produced as described in MATERIALS AND METHODS, and gastrocnemius and soleus muscle were collected at various time points after injury. Values are means ± SE; n = 5 or 6 rats/group. mRNA abundance was expressed in arbitrary units (AUs) determined by densitometry and normalized to 18S mRNA. All data were then normalized to the mean control value determined at 0.5 h. *P < 0.05 compared with time-matched control value.

 

Figure 4
View larger version (34K):
[in this window]
[in a new window]

  		Fig. 4. Acute effect of IGF-I on polyubiquitin (polyUb) mRNA in gastrocnemius (middle) and heart (bottom) from control and burn rats. Tissues were collected 48 h after thermal injury and 4 h after IGF-I administration. polyUb mRNA abundance is expressed in AUs determined by densitometry and normalized to 18S mRNA. Values are means ± SE; n = 8–10 per group. Groups with different letters are significantly different from each other (P < 0.05). Top: representative Northern blots for polyUb in gastrocnemius and heart from the 4 treatment groups. 18S RNA is also shown for each group as a loading control.

 

Figure 6
View larger version (20K):
[in this window]
[in a new window]

  		Fig. 6. Effect of Velcade on gastrocnemius weight (top) and atrogene expression (middle and bottom) after 2 days of burn injury. Rats were pretreated with the proteasome inhibitor or saline 2 h before burn injury. mRNA abundance is expressed in AUs determined by densitometry and normalized to 18S mRNA. Values are means ± SE; n = 6–10 rats per group. Groups with different letters are significantly different from each other (P < 0.05).

 

Figure 7
View larger version (13K):
[in this window]
[in a new window]

  		Fig. 7. Effect of RU-486 on burn-induced atrophy and E3 ligase mRNA content in gastrocnemius. Rats were injected with 20 mg/kg of RU-486 administered subcutaneously 2 h before thermal injury and again 24 h thereafter. Muscle was collected 48 h after the initial thermal injury. Control animals were time matched, pair fed, and injected with an equal volume of vehicle. Top: effect of RU-486 on total protein content of the gastrocnemius. Middle and bottom: effect of RU-486 on burn-induced increase in atrogin-1 and MuRF-1 mRNA content expressed in AUs determined by densitometry and normalized to 18S mRNA. Values are means ± SE; n = 8–10 rats/group. Groups with different letters are significantly different from each other (P < 0.05).

 

View this table:
[in this window]
[in a new window]

  		Table 1. Effect of burn on net protein balance in gastrocnemius

 

   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Temporal changes in gastrocnemius atrogin-1 and MuRF-1 mRNA after burn. In the first study, a limited time-course study was performed to evaluate the temporal progression of burn-induced changes in atrogin-1 and MuRF-1 mRNA in gastrocnemius. Figure 1 illustrates that 40% TBSA burn increased atrogin-1 expression by 12 h, and this increase was maintained for at least 5 days, compared with time-matched control rats. In contrast, the burn-induced increase in MuRF-1 mRNA was more transient and had returned to control values between 3 and 5 days after injury.

Muscle weight and protein content. Forty-eight hours after thermal injury the wet weight of the gastrocnemius was significantly reduced by 9% (Table 1). The protein content (mg protein/g muscle) also tended to be reduced, but this change did not achieve statistical significance (e.g., P < 0.08). As a result of these changes, the total protein per muscle was reduced by 20% (Table 1). We previously determined (42) that the wet weight-to-dry weight ratio is not altered by burn injury at this time point.

Ub ligases and polyUb: effect of IGF-I and leucine. Constitutive expression of atrogin-1 mRNA was observed in both skeletal and cardiac muscle of control rats (Fig. 2). Thermal injury increased atrogin-1 mRNA content of gastrocnemius muscle by 3.1-fold 48 h after injury (Fig. 2). In contrast, atrogin-1 mRNA content was reciprocally downregulated in gastrocnemius from both control and burn rats in response to exogenous IGF-I administration. IGF-I decreased atrogin-1 mRNA by ~50–60% in both groups. However, atrogin-1 expression in the burn + IGF-I group was reduced only back to basal control values. The regulation of atrogin-1 mRNA content differed between cardiac muscle and gastrocnemius in two regards: 1) there was no burn-induced change in atrogin-1 expression in heart under basal conditions, and 2) although IGF-I decreased atrogin-1 in hearts from control rats, no such decline was observed in hearts from burn rats.


Figure 2
View larger version (34K):
[in this window]
[in a new window]

  		Fig. 2. Acute effect of insulin-like growth factor (IGF)-I on atrogin-1 mRNA in gastrocnemius (middle) and heart (bottom) from control and burn rats. Tissues were collected 48 h after thermal injury and 4 h after IGF-I administration. Atrogin-1 mRNA abundance is expressed in AUs determined by densitometry and normalized to 18S mRNA. Values are means ± SE; n = 8–10 per group. Groups with different letters are significantly different from each other (P < 0.05). Top: representative Northern blots for atrogin-1 in gastrocnemius and heart from the four treatment groups. 18S RNA is also shown for each group as a loading control. SAL, saline.

 
Figure 3 illustrates that thermal injury selectively increased MuRF-1 mRNA in gastrocnemius (~8-fold) but not heart. Because of the relatively low constitutive expression of MuRF-1 in skeletal muscle under basal conditions, we were unable to detect a significant change in MuRF-1 expression in gastrocnemius from control rats in response to IGF-I. In contrast, IGF-I treatment decreased MuRF-1 mRNA by 40% in skeletal muscle from burn rats, but the mRNA expression of this E3 ligase remained higher than control values. Neither burn nor IGF-I produced a detectable change in MuRF-1 in cardiac tissue.


Figure 3
View larger version (33K):
[in this window]
[in a new window]

  		Fig. 3. Acute effect of IGF-I on MuRF-1 mRNA in gastrocnemius (middle) and heart (bottom) from control and burn rats. Tissues were collected 48 h after thermal injury and 4 h after IGF-I administration. MuRF-1 mRNA abundance is expressed in AUs determined by densitometry and normalized to 18S mRNA. Values are means ± SE; n = 8–10 per group. Groups with different letters are significantly different from each other (P < 0.05). Top: representative Northern blots for MuRF-1 in gastrocnemius and heart from the 4 treatment groups. 18S RNA is also shown for each group as a loading control.

 
Overall, the change in polyUb mRNA produced by burn or IGF-I was similar to that described above for MuRF-1. For example, burn increased polyUb mRNA in skeletal muscle by twofold. Although this increase in burn muscle was reversed by IGF-I, there was no detectable acute effect of IGF-I on polyUb mRNA in gastrocnemius from control rats (Fig. 4). Again, neither burn nor IGF-I altered polyUb mRNA expression in cardiac muscle at the time points examined.

Ub antibody immunoreactivity was increased in gastrocnemius from burn rats compared with basal control values (Fig. 5). Exogenous IGF-I treatment did not appear to consistently alter the content of ubiquitinated protein in skeletal muscle from either control or burn rats. In contrast to the ability of IGF-I to acutely reduce the mRNA content of atrogin-1, MuRF-1, and polyUb in gastrocnemius from burn rats, the expression of these transcripts was not significantly altered by oral administration of leucine in muscle from either control or burned rats (data not shown).


Figure 5
View larger version (74K):
[in this window]
[in a new window]

  		Fig. 5. Acute effect of IGF-I on Ub conjugates in gastrocnemius and heart from control and burn rats. Tissues were collected 48 h after thermal injury and 4 h after IGF-I administration. A representative Western blot for Ub conjugates in gastrocnemius from the 4 treatment groups is shown. Numbers to the left of Western blot are approximate molecular weights.

 
Differential effect of burn on soleus muscle. In contrast to the burn-induced atrophy observed in gastrocnemius, there was no detectable decrease in the wet weight of the soleus muscle between control and burn rats at either 1 day (127 ± 19 vs. 123 ± 15 mg) or 2 days (129 ± 13 vs. 125 ± 14 mg) after injury. Furthermore, there was no significant change in the mRNA content for atrogin-1 or MuRF-1 in soleus from control and burn rats (data not shown). Because of the lack of change at 24–48 h after burn, we did not determine whether burn altered atrogin-1 and MuRF-1 expression at additional time points.

Proteasome-dependent changes in burn-induced muscle atrophy. In the second experimental protocol the proteasome inhibitor Velcade was administered before burn and the extent of muscle atrophy was studied 48 h later. At this time, the wet weight of the gastrocnemius was significantly reduced by 14% (Fig. 6, top). Velcade pretreatment in vivo completely prevented the burn-induced muscle atrophy. Velcade also prevented the burn-induced decrease in total muscle protein content (data not shown). In a previous study, Velcade was shown not to influence muscle weight in control animals (33), and therefore this drug control was not included in the current study. However, it is important to note that there was a 50% lethality in Velcade-treated burn rats, compared with 0% lethality in saline-treated burn animals. Our previous study (33) indicated no lethality in control rats treated with Velcade.

Northern blot analysis of gastrocnemius from these three experimental groups revealed that Velcade also prevented the large majority of the burn-induced increase in atrogin-1 and MuRF-1 mRNA (Fig. 6, middle and bottom). In this regard, although the atrogene expression in muscle from the burn + Velcade group was significantly greater than untreated control values, Velcade prevented ~50% of the burn-induced increase in atrogin-1 and 85% of the increase in MuRF-1.

Role of endogenous glucocorticoids in regulating burn-induced E3 ligases. In the third experimental protocol rats were administered the glucocorticoid receptor antagonist RU-486 to assess the impact of elevated endogenous corticosterone on muscle atrogin-1 and MuRF-1. Figure 7 illustrates that pretreatment of burned rats with RU-486 did not prevent the burn-induced decrease in muscle protein content or the elevated expression of either atrogin-1 or MuRF-1 mRNA in gastrocnemius.


   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
The present study provides evidence that mRNA expression of atrogin-1 and MuRF-1 is coordinately upregulated in gastrocnemius between 12 h and 3 days after injury. However, at a later time point these atrogenes are differentially regulated. That is, atrogin-1 mRNA content was still increased 5 days after burn, whereas MuRF-1 mRNA had returned to control values by this time point. Hence, although both atrogin-1 and MuRF-1 might mediate the increased muscle proteolysis seen early after burn, any continued acceleration of protein breakdown at later times appears independent of MuRF-1. When examined 48 h after burn, the upregulation of both atrogin-1 and MuRF-1 occurred in the gastrocnemius, a muscle with a predominance of fast-twitch type II fibers, but not the soleus, a muscle composed primarily of slow-twitch type I fibers. Similarly, we confirmed that burn increased polyUb gene expression in the gastrocnemius (8, 18) and extend these observations by demonstrating no such change in soleus. Importantly, changes in E3 ligases and polyUb were closely associated with burn-induced muscle atrophy that was only detected in the gastrocnemius, but not the soleus. These results are consistent with previous studies reporting that the burn-induced stimulation of protein degradation is primarily or exclusively detected in fast-twitch skeletal muscle (8, 17–19). Moreover, the expression of the E3 ligases and polyUb was not increased in heart in response to burn and therefore is an unlikely mediator of any burn-induced protein imbalance in this tissue.

The above-mentioned data indicate a tissue-specific regulation of atrogin-1, MuRF-1, and polyUb after burn and suggest an upregulation of Ub-proteasome-dependent protein degradation in gastrocnemius. This conclusion is supported by two additional lines of evidence. First, there was a corresponding burn-induced increase in Ub immunoreactivity in homogenates of gastrocnemius. Such data corroborate the increased ubiquitinylation of muscle proteins reported in other catabolic conditions (57). Second, pretreatment of animals with the proteasome inhibitor Velcade prevented a significant loss of gastrocnemius weight and protein 2 days after burn injury. These data extend previous studies in which the short-term in vitro incubation of muscles with different proteasome inhibitors attenuated the accelerated proteolysis produced by burn or sepsis (17, 29). Velcade also largely prevented the expression of atrogin-1 and MuRF-1 mRNA; however, the mechanism for this change was not investigated. Finally, although rates of muscle proteolysis were not directly assessed, our findings provide physiological evidence for the relative importance of increased proteasome-dependent proteolysis in mediating the burn-induced atrophy.

The anabolic hormone IGF-I is important for the normal accretion of muscle protein (36), but the circulating and tissue concentration of IGF-I is decreased by burn and other catabolic insults (34, 37, 38, 40). A reduction in bioavailable endogenous IGF-I would be anticipated to increase the rate of muscle proteolysis, whereas exogenous administration should decrease proteolysis (5, 18, 20). Specifically, IGF-I inhibits the breakdown of myofibrillar proteins under both in vitro (8, 18) and in vivo (19) conditions, and this attenuation is associated with a reduction in Ub mRNA content. Our present data indicate that in vivo injection of IGF-I acutely (e.g., within 4 h) reduced the burn-induced elevation in polyUb, atrogin-1, and MuRF-1 in gastrocnemius, and this response appears to be due primarily to a decreased rate of atrogene transcription (56). Collectively, these data are consistent with the ability of IGF-I to decrease whole body and muscle protein breakdown (10, 18) as well as inhibit both lysosomal and Ub-proteasome-dependent protein degradation after burn injury (20). In contrast to the decrement seen in burn rats, IGF-I only decreased atrogin-1 (not MuRF-1 or polyUb) mRNA content in gastrocnemius from control rats. Similar to the gastrocnemius, IGF-I also acutely downregulated atrogin-1 expression in heart from control rats at 4 h. However, a comparable IGF-I-induced decrease in atrogin-1 mRNA was not seen in hearts from burn rats. Collectively, these data suggest that the therapeutic efficacy of IGF-I in skeletal muscle is maintained in adult thermally injured rats.

In contrast to the IGF-I effect, the central nutritional regulator leucine had no detectable effect on atrogene expression in muscle. This was unexpected because IGF-I and leucine mediate their metabolic effects by sharing many of the same distal signaling elements (2). Branched-chain amino acids in general and leucine in particular decrease muscle proteolysis under both in vivo and in vitro conditions (7, 51). Moreover, leucine also dose-dependently inhibits chymotrypsin-like activity of the proteasome (24). Therefore, we anticipated that leucine, similar to IGF-I, would downregulate the expression of atrogin-1 and possibly MuRF-1. However, when the plasma leucine concentration was acutely elevated we were unable to detect a consistent leucine-induced decrease in either constitutive or burn-induced atrogene expression. Hence, the ability of leucine to inhibit muscle proteolysis in rats is not mediated by a concomitant downregulation of atrogene expression. These data further suggest that the mechanism by which IGF-I decreases atrogin-1 mRNA is mediated proximal to phosphatidylinositol 3-kinase (PI3-kinase) and PKB, which are both activated by IGF-I but not by leucine under in vivo conditions (2). This conclusion is consistent with findings from in vitro studies showing that inhibition of PI3-kinase prevents the ability of IGF-I to decrease atrogin-1 (56) and that adenoviral infection of myocytes with a dominant-negative PI3-kinase suppresses the inhibitory effect of insulin on protein degradation (46). Because of the acute nature of the present experimental protocol, we cannot exclude the possibility that a more chronic elevation in leucine would downregulate atrogene expression.

Burn injury produces a rapid and sustained elevation in the circulating concentration of glucocorticoids (16, 35, 41). Moreover, the catabolic effect of exogenously administered glucocorticoids, primarily dexamethasone, is well established in skeletal muscle and consistently characterized by an increased rate of degradation. Although dexamethasone dramatically increases proteolysis by stimulating various proteolytic pathways (9, 47, 57), this stimulation is associated with increased expression of atrogin-1 and MuRF-1 and can be largely inhibited by pretreatment with proteasome inhibitors (6, 56, 57). These data imply that dexamethasone-induced muscle wasting is primarily mediated by the Ub-proteasome pathway. Moreover, administration of the glucocorticoid receptor antagonist RU-486 prevents the decrement in muscle proteolysis seen in response to sepsis or burn (16, 57). The results of the present study, however, fail to confirm that the burn-induced increase in muscle proteolysis is mediated by endogenous glucocorticoids. Instead, our data on muscle weight as well as the mRNA content for atrogin-1, MuRF-1, and polyUb indicate that the increased rate of muscle proteolysis is glucocorticoid independent. These data corroborate an early study by Clark et al. (11) in which the burn-induced increase in muscle proteolysis was not ameliorated by either adrenalectomy or inhibition of glucocorticoid synthesis with metyrapone. Although the exact reason for this apparent discrepancy is not known, studies showing glucocorticoid dependence used smaller immature rats (40–60 g) compared with those studies purporting a glucocorticoid-independent effect (>250 g). In this regard, the rate of myofibrillar breakdown has been reported to be threefold greater in muscles from immature rats compared with rates in mature animals (64). Alternatively, it has been posited that a second signal, such as low insulin, might be required for glucocorticoids to activate muscle proteolysis (45). However, this permissive effect of insulinopenia would not be expected because the circulating insulin concentration is well preserved after burn in adult rats (39, 35). Finally, a glucocorticoid-independent activation of the Ub system has also been observed in cancer cachexia (48).

It is noteworthy that despite the ability of Velcade to prevent the atrophic response of fast-twitch skeletal muscle to burn injury, this proteasome inhibitor markedly increased mortality in burned rats. Previous studies in our lab (33) using the same Velcade dose and weight and strain of rats did not indicate any lethality in control animals. We have no direct evidence related to the cause of this increased mortality; however, a more thorough investigation of this adverse effect is certainly warranted.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported in part by National Institutes of Health Grants GM-38032 and HL-66443, and the Pennsylvania Department of Health Tobacco Settlement Fund.


   ACKNOWLEDGMENTS
 
We thank Dr. Vincent Chau for his helpful discussions.


   FOOTNOTES
 

Address for reprint requests and other correspondence: C. H. Lang, Dept. of Cell and Molecular Physiology, H166, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033 (e-mail: clang{at}psu.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615–2622, 1999.[Abstract/Free Full Text]
  2. Anthony JC, Anthony TG, Kimball SR, Jefferson LS. Signaling pathways involved in translational control of protein synthesis in skeletal muscle by leucine. J Nutr 131: 856S–860S, 2001.[Abstract/Free Full Text]
  3. Anthony JC, Lang CH, Crozier SJ, Anthony TG, MacLean DA, Kimball SR, Jefferson LS. Contribution of insulin to the translational control of protein synthesis in skeletal muscle by leucine. Am J Physiol Endocrinol Metab 282: E1092–E1101, 2002.[Abstract/Free Full Text]
  4. Banta S, Yokoyama T, Berthiaume F, Yarmush ML. Quantitative effects of thermal injury and insulin on the metabolism of the skeletal muscle using the perfused rat hindquarter preparation. Biotechnol Bioeng 88: 613–629, 2004.[CrossRef][Web of Science][Medline]
  5. Bark TH, McNurlan MA, Lang CH, Garlick PJ. Increased protein synthesis after acute IGF-I or insulin infusion is localized to muscle in mice. Am J Physiol Endocrinol Metab 275: E118–E123, 1998.[Abstract/Free Full Text]
  6. Bodine SC, Latres E, Baumheter S, Lai VK, Nunez L, Clarke BA, Pouevmirou WT, Panaro FJ, Na EM, Stitt TN, Yancopoulos GD, Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704–1708, 2001.[Abstract/Free Full Text]
  7. Buse MG, Reid SS. Leucine: a possible regulator of protein turnover in muscle. J Clin Invest 56: 1250–1261, 1975.[Web of Science][Medline]
  8. Chai J, Wu Y, Sheng Z. The relationship between skeletal muscle proteolysis and ubiquitin-proteasome proteolytic pathway in burned rats. Burns 28: 527–533, 2002.[CrossRef][Web of Science][Medline]
  9. Chrysis D, Underwood LE. Regulation of components of the ubiquitin system by insulin-like growth factor I and growth hormone in skeletal muscle or rats made catabolic with dexamethasone. Endocrinology 140: 5635–5641, 1999.[Abstract/Free Full Text]
  10. Cioffi WG, Gore DC, Rue LW, Carrougher G, Guler HP, McManus WF, Pruitt BA. Insulin-like growth factor-I lowers protein oxidation in patients with thermal injury. Ann Surg 220: 310–319, 1994.[Web of Science][Medline]
  11. Clark AS, Kelly RA, Mitch WE. Systemic response to thermal injury in rats. Accelerated protein degradation and altered glucose utilization in muscle. J Clin Invest 74: 888–897, 1984.[Web of Science][Medline]
  12. Dardevet D, Sornet C, Savary I, Debras E, Patureau-Mirand P, Grizard J. Glucocorticoid effects on insulin- and IGF-I-regulated muscle protein metabolism during aging. J Endocrinol 156: 83–89, 1998.[Abstract]
  13. Dehoux MJM, van Beneden RP, Gernandez-Celemin L, Lause PL, Thissen JPM. Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. FEBS Lett 544: 214–217, 2003.[CrossRef][Web of Science][Medline]
  14. Fagan JM, Ganguly M, Stockman H, Ferland LH, Toner M. Posttranslational modifications of cardiac and skeletal muscle proteins by reactive oxygen species after burn injury in the rat. Ann Surg 229: 106–114, 1999.[CrossRef][Web of Science][Medline]
  15. Fan J, Wojnar MM, Theodorakis M, Lang CH. Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1. Am J Physiol Regul Integr Comp Physiol 270: R621–R629, 1996.[Abstract/Free Full Text]
  16. Fang CH, James HJ, Ogle C, Fischer JE, Hasselgren PO. Influence of burn injury on protein metabolism in different types of skeletal muscle and the role of glucocorticoids. J Am Coll Surg 180: 33–42, 1995.[Web of Science][Medline]
  17. Fang CH, Li BG, Fischer DR, Wang JJ, Runnels HA, Monaco JJ, Hasselgren PO. Burn injury upregulates the activity and gene expression of the 20 S proteasome in rat skeletal muscle. Clin Sci (Lond) 99: 181–187, 2000.[Medline]
  18. Fang CH, Li BG, Wang JJ, Fischer JE, Hasselgren PO. Insulin-like growth factor 1 stimulates protein synthesis and inhibits protein breakdown in muscle from burned rats. J Parenter Enteral Nutr 21: 245–251, 1997.[Abstract/Free Full Text]
  19. Fang CH, Li BG, Wang JJ, Fischer JE, Hasselgren PO. Treatment of burned rats with insulin-like growth factor I inhibits the catabolic response in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 275: R1091–R1098, 1998.[Abstract/Free Full Text]
  20. Fang CH, Li BG, Wray CJ, Hasselgren PO. Insulin-like growth factor I inhibits lysosomal and proteasome-dependent proteolysis in skeletal muscle after burn injury. J Burn Care Rehabil 23: 318–325, 2002.[CrossRef][Web of Science][Medline]
  21. Fang CH, Sun X, Li BG, Fischer DR, Pritts TA, Penner G, Hasselgren PO. Burn injuries in rats upregulates the gene expression of the ubiquitin-conjugating enzyme E214k in skeletal muscle. J Burn Care Rehabil 21: 528–534, 2000.[Web of Science][Medline]
  22. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98: 14440–14445, 2001.[Abstract/Free Full Text]
  23. Griffiths RD, Jones C, Palmer TE. Outcome of nutrition therapies in the intensive care unit. Nutrition 11: 224–228, 1995.[Web of Science][Medline]
  24. Hamel FG, Upward JL, Siford GL, Dockworth WC. Inhibition of proteasome activity by selected amino acids. Metabolism 52: 810–814, 2003.[CrossRef][Web of Science][Medline]
  25. Hart DW, Wolf SE, Micak R, Chinkes DL, Ramzy PI, Obeng MK, Ferrando AA, Wolfe RR, Herndon DN. Persistence of muscle catabolism after severe burn injury. Surgery 128: 312–319, 2000.[CrossRef][Web of Science][Medline]
  26. Hasselgren PO. Protein Metabolism in Sepsis. Austin, TX: Landes, 1993.
  27. Hasselgren PO, Fischer JE. Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 233: 9–17, 2001.[CrossRef][Web of Science][Medline]
  28. Hasselgren PO, Wray C, Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun 290: 1–10, 2002.[CrossRef][Web of Science][Medline]
  29. Hobler SC, Tiao G, Fischer JE, Monaco J, Hasselgren PO. Sepsis-induced increase in muscle proteolysis is blocked by specific proteasome inhibitors. Am J Physiol Regul Integr Comp Physiol 274: R30–R37, 1998.[Abstract/Free Full Text]
  30. Hu RH, Yu YM, Casta D, Young VR, Ryan CM, Burke JF, Tompkins RG. A rabbit model for metabolic studies after burn injury. J Surg Res 75: 153–160, 1998.[CrossRef][Web of Science][Medline]
  31. Ibebunjo C, Martyn J. Disparate dysfunction of skeletal muscles located near and distant from burn site in the rat. Muscle Nerve 24: 1283–1294, 2001.[CrossRef][Web of Science][Medline]
  32. Jahoor F, Desai M, Herndon DN, Wolfe RR. Dynamics of the protein metabolic response to burn injury. Metabolism 37: 330–337, 1988.[CrossRef][Web of Science][Medline]
  33. Krawiec BJ, Frost RA, Vary TC, Jefferson LS, Lang CH. Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis. Am J Physiol Endocrinol Metab 289: E969–E980, 2005.[Abstract/Free Full Text]
  34. Lang CH, Fan J, Cooney R, Vary TC. Interleukin-1 receptor antagonist attenuates sepsis-induced alterations in the insulin-like growth factor system and protein synthesis. Am J Physiol Endocrinol Metab 270: E430–E437, 1996.[Abstract/Free Full Text]
  35. Lang CH, Fan J, Frost RA, Gelato MC, Sakurai Y, Herndon DN, Frost RR. Regulation of the insulin-like growth factor system by insulin in burn patients. J Clin Endocrinol Metab 81: 2474–2480, 1996.[Abstract]
  36. Lang CH, Frost RA. Effect of insulin-like growth factor proteins on skeletal muscle protein metabolism during normal and catabolic conditions. In IGF, Nutrition and Health, edited by Houston SM, Holly JMP, Feldman EL. Totowa, NJ: Humana, 2004, p 67–83.
  37. Lang CH, Frost RA, Jefferson LS, Kimball SR, Vary TC. Endotoxin-induced decrease in muscle protein synthesis is associated with alterations in eIF2B, eIF4E, and IGF-I. Am J Physiol Endocrinol Metab 278: E1133–E1143, 2000.[Abstract/Free Full Text]
  38. Lang CH, Frost RA, Narn AC, MacLean DA, Vary TC. TNF-{alpha} decreases myocardial and skeletal muscle protein synthesis via alterations in translation initiation but not elongation. Am J Physiol Endocrinol Metab 282: E336–E347, 2002.[Abstract/Free Full Text]
  39. Lang CH, Frost RA, Vary TC. Thermal injury impairs cardiac protein synthesis and is associated with alterations in translation initiation. Am J Physiol Regul Integr Comp Physiol 286: R740–R750, 2004.[Abstract/Free Full Text]
  40. Lang CH, Liu X, Nystrom GJ, Frost RA. Acute response of IGF-I and IGF binding proteins induced by thermal injury. Am J Physiol Endocrinol Metab 278: E1087–E1096, 2000.[Abstract/Free Full Text]
  41. Lang CH, Nystrom GJ, Frost RA. Burn-induced changes in IGF-I and IGF-binding proteins are partially glucocorticoid dependent. Am J Physiol Regul Integr Comp Physiol 282: R207–R215, 2002.[Abstract/Free Full Text]
  42. Lang CH, Silvis C, Nystrom G, Frost RA. Regulation of myostatin by glucocorticoids after thermal injury. FASEB J 15: 1807–1809, 2001.[Free Full Text]
  43. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996–5000, 2002.[Abstract/Free Full Text]
  44. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39–51, 2004.[Abstract/Free Full Text]
  45. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 129: 227S–237S, 1999.[Free Full Text]
  46. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 15: 1537–1545, 2004.[Abstract/Free Full Text]
  47. Li BG, Hasselgren PO, Fang CH, Warden GD. Insulin-like growth factor-I blocks dexamethasone-induced protein degradation in cultured myotubes by inhibiting multiple proteolytic pathways. J Burn Care Rehabil 25: 112–118, 2004.[CrossRef][Web of Science][Medline]
  48. Llovera M, Garcia-Martinez C, Costelli P, Agell N, Carbo N, Lopez-Soriano FJ, Argiles JM. Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. Cancer Lett 99: 7–14, 1996.[CrossRef][Web of Science][Medline]
  49. Mao J, Regelson W, Kalimi M. Molecular mechanism for RU486 action: a review. Mol Cell Biochem 109: 1–8, 1992.[Web of Science][Medline]
  50. Mitch WE, Goldberg AL. Mechanism of muscle wasting. N Engl J Med 335: 1897–1905, 1996.[Free Full Text]
  51. Nakashima K, Ishida A, Yamazaki M, Abe H. Leucine suppresses myofibrillar proteolysis by down-regulating ubiquitin-proteasome pathway in chick skeletal muscles. Biochem Biophys Res Commun 336: 660–666, 2005.[CrossRef][Web of Science][Medline]
  52. Odessey R. Burn-induced stimulation of lysosomal enzyme activity in skeletal muscle. Metabolism 35: 750–757, 1986.[CrossRef][Web of Science][Medline]
  53. Odessey R, Parr B. Effect of insulin and leucine on protein turnover in rat soleus muscle after burn injury. Metabolism 31: 82–87, 1982.[Web of Science][Medline]
  54. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J, Grisham MB. Role of the proteasome and NF-{kappa}B in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 95: 15671–15676, 1998.[Abstract/Free Full Text]
  55. Roos-Mattjus P, Sistonen L. The ubiquitin-proteasome pathway. Ann Med 36: 285–295, 2004.[CrossRef][Web of Science][Medline]
  56. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 287: E591–E601, 2004.[Abstract/Free Full Text]
  57. Tiao G, Fagan J, Roegner V, Lieberman M, Wang JJ, Fischer JE, Hasselgren PO. Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J Clin Invest 97: 339–348, 1996.[Web of Science][Medline]
  58. Walker HL, Mason AD. A standard animal burn. J Trauma 8: 1049–1051, 1968.[Web of Science][Medline]
  59. Windsor JA, Hill GL. Risk factors for postoperative pneumonia. The importance of protein depletion. Ann Surg 208: 209–214, 1988.[Web of Science][Medline]
  60. Windsor JA, Hill GL. Weight loss with physiologic impairment. A basic indicator of surgical risk. Ann Surg 207: 290–296, 1988.[Web of Science][Medline]
  61. Wolfe RR. Acute versus chronic responses to burn injury. Circ Shock 8: 105–115, 1981.[Web of Science][Medline]
  62. Wray CJ, Mammen JMV, Hershko DD, Hasselgren PO. Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. Int J Biochem Cell Biol 35: 698–705, 2003.[CrossRef][Web of Science][Medline]
  63. Xu J, Fei Z, Yu YM, Xu W, Rhodes AN, Tompkins RG, Schulz JT. In vivo rabbit hindquarter model for assessment of regional burn hypermetabolism. J Appl Physiol 94: 135–140, 2003.[Abstract/Free Full Text]
  64. Zamir O, Hasselgren PO, Frederick JA, Fischer JE. Is the metabolic response to sepsis in skeletal muscle different in infants and adults? An experimental study in rats. J Pediatr Surg 27: 1399–1403, 1992.[CrossRef][Web of Science][Medline]
  65. Zamir O, Hasselgren PO, von Allmen D, Fischer JE. The effect of interleukin-1{alpha} and the glucocorticoid receptor blocker RU38486 on total and myofibrillar protein breakdown in skeletal muscle. J Surg Res 50: 570–583, 1991.



This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
Q. Jiao, A. M. Pruznak, D. Huber, T. C. Vary, and C. H. Lang
Castration differentially alters basal and leucine-stimulated tissue protein synthesis in skeletal muscle and adipose tissue
Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E1222 - E1232.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
A. U. Trendelenburg, A. Meyer, D. Rohner, J. Boyle, S. Hatakeyama, and D. J. Glass
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Am J Physiol Cell Physiol, June 1, 2009; 296(6): C1258 - C1270.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. Balasubramaniam, R. Joshi, C. Su, L. A. Friend, S. Sheriff, R. J. Kagan, and J. H. James
Ghrelin inhibits skeletal muscle protein breakdown in rats with thermal injury through normalizing elevated expression of E3 ubiquitin ligases MuRF1 and MAFbx
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R893 - R901.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. L Novak, W. Billich, S. M. Smith, K. B. Sukhija, T. J. McLoughlin, T. A. Hornberger, and T. J. Koh
COX-2 inhibitor reduces skeletal muscle hypertrophy in mice
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1132 - R1139.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
T. C. Vary, R. A. Frost, and C. H. Lang
Acute alcohol intoxication increases atrogin-1 and MuRF1 mRNA without increasing proteolysis in skeletal muscle
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2008; 294(6): R1777 - R1789.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. W. H. van Hees, Y.-P. Li, C. A. C. Ottenheijm, B. Jin, C. J. C. Pigmans, M. Linkels, P. N. R. Dekhuijzen, and L. M. A. Heunks
Proteasome inhibition improves diaphragm function in congestive heart failure rats
Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1260 - L1268.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C.-H. Fang, B. Li, J. H. James, A. Yahya, N. Kadeer, X. Guo, C. Xiao, D. M. Supp, R. J. Kagan, P.-O. Hasselgren, et al.
GSK-3beta activity is increased in skeletal muscle after burn injury in rats
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1545 - R1551.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
R. A. Frost and C. H. Lang
Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass
J Appl Physiol, July 1, 2007; 103(1): 378 - 387.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/1/R328    most recent
00561.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lang, C. H.
Right arrow Articles by Frost, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lang, C. H.
Right arrow Articles by Frost, R. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.